iStent inject 在开角型青光眼患者中的长期内皮安全性特征
本文报告了 iStent inject 关键性随机对照试验的5年随访安全性数据,纳入227例轻中度原发性开角型青光眼患者,比较 iStent inject 联合超声乳化与单纯超声乳化。结果显示至术后60个月无器械相关不良事件,两组内皮细胞密度变化及>30%内皮细胞丢失比例均无显著差异。
要点
- 至术后60个月,iStent inject 组未报告器械相关不良事件或并发症。
- 60个月时 iStent inject 组平均内皮细胞密度下降14.3%±13.4%,对照组下降14.8%±10.3%(P=0.8112)。
- 各时间点两组平均内皮细胞密度、平均百分比变化及>30%内皮细胞丢失比例均无显著差异。
核心结论
- 在轻中度原发性开角型青光眼患者中,超声乳化术中植入 iStent inject 至术后60个月未产生器械相关并发症或内皮细胞密度安全性问题。
研究设计与样本
- 为期5年的随访安全性研究,基于前瞻性、随机、单盲、平行对照、多中心 iStent inject 关键性试验的2年随机对照试验。
- 原始随机患者505例,其中227例参与本次随访:iStent inject 联合超声乳化组178例,单纯超声乳化对照组49例。
主要发现
- 至术后60个月,未报告具体的器械相关不良事件或并发症。
- 各时间点两组平均内皮细胞密度、平均内皮细胞密度百分比变化及>30%内皮细胞丢失眼比例均无显著差异。
- 60个月时平均内皮细胞密度下降:iStent inject 组14.3%±13.4%,对照组14.8%±10.3%(P=0.8112)。
- 3至60个月内皮细胞密度年化变化率在两组间无临床或统计学显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report 5-year postoperative safety data of iStent inject, including overall stability, endothelial cell density (ECD), and endothelial cell loss (ECL) in patients with mild-to-moderate primary open-angle glaucoma (POAG). DESIGN: 5-year follow-up safety study of the prospective, randomized, single-masked, concurrently controlled, multicenter iStent inject pivotal trial. METHODS: In this 5-year follow-up safety study of the 2-year iStent inject pivotal randomized controlled trial, patients receiving iStent inject placement and phacoemulsification or phacoemulsification alone were studied for the incidence of clinically relevant complications associated with iStent inject placement and stability. Corneal endothelial endpoints were mean change in ECD from screening and proportion of patients with >30% ECL from screening, from analysis of central specular endothelial images by a central image analysis reading center at several time points through 60 months postoperatively. RESULTS: Of the 505 original randomized patients, 227 elected to participate (iStent inject and phacoemulsification group, n = 178; phacoemulsification-alone control group, n = 49). No specific device-related adverse events or complications were reported through month 60. No significant differences were observed in mean ECD, mean percentage change in ECD, or proportion of eyes with >30% ECL between the iStent inject and control groups at any time point; mean percentage decrease in ECD at 60 months was 14.3% ± 13.4% in the iStent inject group and 14.8% ± 10.3% in the control group (P = .8112). The annualized rate of ECD change from 3 to 60 months was neither clinically nor statistically significant between groups. CONCLUSIONS: Implantation of iStent inject during phacoemulsification in patients with mild-to-moderate POAG did not produce any device-related complications or ECD safety concerns compared to phacoemulsification alone through 60 months.
引用
- Ahmed IIK, Sheybani A, De Francesco T, et al. Long-Term Endothelial Safety Profile With iStent Inject in Patients With Open-Angle Glaucoma. Am J Ophthalmol. 2023. PMID: 36868339. doi:10.1016/j.ajo.2023.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。